TJ-L1I7

**TJ-L1I7** is an investigational **PD-L1-targeted antibody-cytokine fusion protein** being developed by **I-Mab** for oncology, particularly **solid tumors**. It consists of an anti-PD-L1 antibody fused to **interleukin-7**, with the intended dual mechanism of **blocking the PD-1/PD-L1 immune checkpoint axis** while simultaneously delivering **IL-7-mediated T-cell expansion and functional support** in the tumor microenvironment. The program has been described by the company as a strategy to increase both the number and activity of tumor-infiltrating T cells and convert immunologically cold tumors into more immune-responsive hot tumors. Publicly available pipeline sources indicate the asset remained **preclinical** and has also been listed in some databases as **discontinued**, so its exact current development disposition is uncertain across sources.